Eyeworld Daily News

55 EW SHOW DAILY ASCRS•ASOA Symposium & Congress, Los Angeles 2017 Inder Paul Singh, MD, Racine, Wisconsin, addressed logistical and clinical factors involved with adding subconjunctival MIGS to a cata- ract practice. Some considerations include the learning curve, bleb management, reimbursement, and patient flow. However, these factors are all manageable, he added. However, it will become smaller and more functional after that. In terms of postop manage- ment, don't panic if hypotony occurs within the first week. This is fine so long as the visual acuity is still good. "The pressure will usually go up in the next week," Dr. Stal- mans said. With the growth in combined cataract and glaucoma surgery, Dr. Stalmans addressed whether a cata- ract surgeon can implant the XEN. "Yes, they can, but the question is whether they can manage the bleb postop," she said. Be prepared to be "wed" to your patient for a month to monitor progress. Adding MIGS to his mix has changed Dr. Singh's definition of what controlled glaucoma is. "I now am able to put quality of life into the definition of what is controlled glaucoma," he said. EW Editors' note: This event was supported by an educational grant from Allergan. INDICATIONS AND USAGE PROLENSA ® (bromfenac ophthalmic solution) 0.07% is a nonsteroidal anti-infl ammatory drug (NSAID) indicated for the treatment of postoperative infl ammation and reduction of ocular pain in patients who have undergone cataract surgery. IMPORTANT SAFETY INFORMATION ABOUT PROLENSA ® • PROLENSA ® contains sodium sulfi te, a sulfi te that may cause allergic type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfi te sensitivity in the general population is unknown and probably low. Sulfi te sensitivity is seen more frequently in asthmatic than in non-asthmatic people. • All topical nonsteroidal anti-infl ammatory drugs (NSAIDs), including bromfenac, may slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems. • There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs, including bromfenac. Use with caution in patients who have previously exhibited sensitivities to these drugs. • There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery. Use with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time. • Use of topical NSAIDs may result in keratitis. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs, including bromfenac, and should be closely monitored for corneal health. Patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients. Post-marketing experience with topical NSAIDs suggests that use more than 24 hours prior to surgery or use beyond 14 days post-surgery may increase patient risk for the occurrence and severity of corneal adverse events. • PROLENSA ® should not be instilled while wearing contact lenses. The preservative in PROLENSA ® , benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of PROLENSA ® . • The most commonly reported adverse reactions in 3%-8% of patients were anterior chamber infl ammation, foreign body sensation, eye pain, photophobia, and blurred vision. Please see brief summary of full Prescribing Information for PROLENSA ® on adjacent page. References: 1. PROLENSA Prescribing Information, April 2013. 2. Data on fi le, Bausch & Lomb Incorporated. 3. Baklayan GA, Patterson HM, Song CK, Gow JA, McNamara TR. 24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand white rabbits. J Ocul Pharmacol Ther. 2008;24(4):392-398. PROLENSA is a registered trademark of Bausch & Lomb Incorporated or its affi liates. © Bausch & Lomb Incorporated. All rights reserved. Printed in USA. PRA.0188.USA.15 The PROLENSA ® Effect POWERED FOR PENETRATION Advanced Formulation to Facilitate Corneal Penetration 1-3 pH e ffect Hal og en a ti on e ffect PROLENSA ® delivers potency and corneal penetration with QD dosing at a low concentration 1-3 digital. eyeworld.org Featuring: Advances in corneal inlays History, the current market, and what's yet to come — P. 86 Pros and cons of inlays — P. 89 Corneal inlay candidate selection — P. 91 Testing corneal inlays — P. 95 Inlays among other presbyopia treatments — P. 98 Implanting corneal inlays — P. 100 Table of contents P. 4, 6, 8 Pearls for dealing with a rock hard nucleus — P. 66 Vol. 22, No. 3 March 2017 The news magazine of the American Society of Cataract & Refractive Surgery USA digital.eyeworld.org An ASCRS Publication Prepping the ocular surface — P. 80 ASCRS•ASOA city preview — P. 42 Aqueous outflow and MIGS — P. 108 Featuring: Controversies in cataract surgery Artificial iris implantation devices in the U.S. — P. 108 Intracameral antibiotics — P. 110 Going dropless — P. 114 NSAID use during cataract surgery — P. 118 Vancomycin-associated HORV — P. 122 Immediately sequential bilateral cataract surgery — P. 126 Table of contents P. 6, 8, 10, 12 Prepping the ocular surface: Lumps and bumps — P. 100 An ASCRS Publication ASCRS•ASOA Show Issue VOL. 22, NUMBER 4 April 2017 The news magazine of the American Society of Cataract & Refractive Surgery USA digital.eyeworld.org Mediterranean diet for AMD prevention — P. 158 ASCRS•ASOA preview — P. 44 Phaco turns 50 — P. 130 2 Good friends and great education in a vibrant city. Join us in Los Angeles! Featuring: Treating the cornea before cataract surgery Preop corneal irregularity approaches for cataract patients — P. 46 Tips to diagnose corneal lumps and bumps — P. 48 Optimizing the ocular surface with amniotic membrane therapy — P. 50 Primer for dry eye diagnosis and treatment before cataract surgery — P. 56 Table of contents P. 4, 6 Getting beyond the dry front: Update on immunomodulation for dry eye disease — P. 62 An ASCRS Publication Vol. 22, No. 5 May 2017 The news magazine of the American Society of Cataract & Refractive Surgery USA digital.eyeworld.org Novel glaucoma therapies — P. 74 Posterior corneal astigmatism — P. 32 Lens, laser, or nothing? — P. 42 2

• Cover